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In Europe the incidence of human Q fever has dra-
matically increased over the previous years. Untreated 
infections with Coxiella burnetii, the causal agent 
of Q fever, have been associated with both obstetric 
and maternal complications. The majority of pregnant 
women with a C.  burnetii infection remain asympto-
matic, hence screening could be of value to prevent 
unwanted outcomes in this high-risk group. We applied 
the updated Wilson and Jungner criteria to review the 
evidence for routine screening for C. burnetii infection 
during pregnancy. Since much uncertainty remains 
about the incidence, clinical consequences, diag-
nostics and treatment of C.  burnetii infection during 
pregnancy, routine screening for C.  burnetii infec-
tion during pregnancy should not be recommended. 
Rigorous studies to assess the effectiveness of C. bur-
netii screening are warranted.
Introduction
Infections during pregnancy may cause a threat to 
both maternal and foetal health, even if the infected 
pregnant woman herself remains asymptomatic [1]. 
Therefore, routine screening at 12 weeks of gestation is 
being offered to all Dutch pregnant women for human 
immunodeficiency virus (HIV), Treponema pallidum and 
hepatitis B virus (HBV). The incidence of human Q fever, 
a zoonosis caused by Coxiella burnetii, showed an enor-
mous increase in the Netherlands and other European 
countries over the past few years [2]. Since there is evi-
dence for infection-associated obstetric and maternal 
complications, C.  burnetii infection poses a potential 
risk to pregnant women and their (unborn) children 
[3]. Most of the pregnant women with a C.  burnetii 
infection remain asymptomatic [4]. Therefore routine 
screening has been put forward for early detection and 
treatment in this group, but scientific evidence about 
the usefulness of such an intensive program is lack-
ing. In this review we applied the Wilson and Jungner 
criteria according to the World Health Organization to 
scrutinise the available evidence for routine screening 
for C. burnetii infection during pregnancy. These crite-
ria were developed over 40 years ago but are still of 
great value in decision making around screening poli-
cies [5]. The criteria centre on the problem caused by 
the infection or disease, the screening population, the 
test and the treatment, and the costs. As newer policy 
tools, especially concerning genetic screening, have 
been suggested [6], we also integrated the emerging 
criteria which are applicable to our research ques-
tion. A review of the literature was done by searching 
PubMed and the references of included papers. Our 
search was limited to studies in English or Dutch. The 
search strategy included the keywords ’Q fever’ or 
‘Coxiella burnetii’ and keywords related to the criteria 
(‘incidence’ or ‘prevalence’ or ‘pregnancy’ or ‘risk fac-
tors’ or ‘diagnosis’ or ‘treatment’ or ‘costs’). Our over-
all aim was to examine the evidence base for routine 
C.  burnetii screening among pregnant women in high-
risk areas for Q fever all over Europe.
The problem
Terminology used in the scientific literature concerning 
’Q fever‘ is diverse and therefore direct comparisons of 
epidemiological studies should be performed with cau-
tion. ‘Q fever’ is commonly referred to the symptomatic 
disease, including symptoms such as fever, hepatitis 
or pneumonia in combination with positive antibody 
titres or polymerase chain reaction (PCR). The terms 
‘C.  burnetii infection’ and ‘presence of antibodies’ are 
more often used in the context of asymptomatic dis-
ease, for example, in prevalence studies.
Is Coxiella burnetii infection during 
pregnancy an important health problem?
Prior to 2007 Q fever was uncommon in Europe [2], 
except from some local outbreaks such as the outbreak 
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in Germany in spring 2005, causing 331 cases [7]. In 
the Netherlands around 10 to 30 cases have been noti-
fied each year since 1977. Between 2007 and 2009 the 
numbers briskly increased to over 2,300 cases in 2009, 
the highest number ever reported in the literature [8]. 
Veterinary outbreaks on several dairy goat and sheep 
farms in the southern parts of the Netherlands are held 
responsible for this increase. In 2009 and 2010 it was 
decided to implement extensive measures such as vac-
cinating and culling of thousands of animals [8]. As a 
result, the number of human Q fever cases decreased 
rapidly to around 500 cases by the end of 2010, which 
is still considerable and may indicate an endemic stage 
[9]. Also other European countries, such as Belgium, 
Cyprus and Germany have reported an increasing 
number of cases since 2007, albeit to a smaller extent 
[2].
The prevalence of Q fever among pregnant women 
is unknown. Recently published data from the 
Netherlands showed a prevalence of immunoglobulin 
(Ig)M, suggesting recent infection with C.  burnetii, in 
3.4% of 1,646 tested serum samples from pregnant 
women in Q fever high-risk areas [10]. In a cohort study 
from Canada, 3.8% of parturient women had evidence 
of previous exposure to C.  burnetii (presence of IgG 
phase I and/or II). These women had, in contrast to 
the Dutch seropositive women [10], a higher risk for 
adverse pregnancy outcomes, in terms of premature 
delivery and prior or current neonatal death, compared 
with seronegative women [11]. A milestone hospital-
based study from France showed that 81% of the preg-
nant women with untreated Q fever had a miscarriage, 
premature delivery, intrauterine growth restriction or 
foetal death. Furthermore, chronic Q fever occurred in 
50% of the cases, of whom 10% developed C. burnetii 
endocarditis [3]. These figures are alarming, but need 
to be cautiously interpreted as the retrospective design 
covering many years may have led to some overestima-
tion of risks. Certainly, this study together with the 
prevalence studies emphasise that C. burnetii infection 
is a potential threat to pregnant women.
Is there a latent or early symptomatic stage?
Up to 90% of infected pregnant women remain asymp-
tomatic [4]. Therefore, early detection, before obstet-
ric complications and maternal chronic Q fever have 
occurred, enables treatment that may prevent compli-
cations due to C. burnetii infection [3].
Is the natural history of Coxiella burnetii 
infection adequately understood?
C. burnetii is a small gram-negative intracellular living 
bacterium. The main route of transmission is the res-
piratory route, in which alveolar macrophages in the 
lungs are the first cells to be infected [12]. Furthermore, 
the placenta seems to be a target organ since placen-
titis has been described in both animals and humans 
[3,13]. After the primary infection, C.  burnetii has the 
ability to induce chronic infections. It is hypothesised 
that, besides the liver, bone, heart valves and mural 
endocardium [14], the uterus could be a site of latent 
infection, hence reactivation during pregnancy can 
occur [3,11].
The pathogenesis of obstetric complications following 
infection is not completely understood; immune com-
plexes may cause vasculitis and vascular thrombosis, 
which in turn may lead to the placental insufficiency 
and subsequent obstetric complications [15]. Also, 
direct transplacental transmission by C.  burnetii may 
cause foetal death [16]. Obstetric complications occur 
significantly more often in patients who are infected 
during the first trimester of pregnancy than in those 
infected later [3].
Not only have acute infections been associated with 
obstetric complications, but also previous infections 
seem to increase the risk [11]. There is no good expla-
nation for this association besides the hypothesis 
of intrauterine latency of the infection [11]. In all, the 
natural history of C. burnetii infection among pregnant 
women is not completely understood.
The screening population
Since the Q fever incidence largely varies between 
regions (see for example the situation in the 
Netherlands, figure), the population for routine screen-
ing should be limited to pregnant women living in high-
risk Q fever areas. Women living within a five-kilometre 
zone around a dairy goat or dairy sheep farm affected 
by C. burnetii-related abortion waves have the highest 
risk of contracting an infection, however, still 41% of 
the Dutch cases in 2009 lived outside of these areas [8]. 
Whether these cases visited the five-kilometre zones is 
unclear. Therefore, if introduced, routine screening of 
all pregnant women would be advisable in areas with a 
high incidence (e.g. >50/100,000 inhabitants). So, with 
a good surveillance system, the screening population 
can be accurately defined. Screening of specific groups 
at risk, e.g. pregnant women with occupational hazard 
for Q fever or with complicated pregnancies can also 
be considered, but is beyond the scope of this study 
discussing routine screening of a total population.
Similar to other screening programs during pregnancy, 
eligible women have to be counselled about the ben-
efits and possible consequences of the screening 
(i.e. long-term antibiotic treatment and hospital birth 
instead of home birth in case of an acute infection, 
stress induced by awareness of infectious diseases 
during pregnancy) to be able to make an informed 
choice about participation.
Is there an agreed policy on whom to treat as patients?
All phases of C.  burnetii infection during pregnancy 
have been associated with adverse pregnancy out-
come. However, evidence for the benefits of antibi-
otic treatment is only available in patients with acute 
and chronic Q fever [3]. Whether antibiotic treatment 
prevents complications in women with asymptomatic 
seropositivity needs to be investigated.
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Is case finding a continuing process 
and not a ’once and for all‘ project?
If introduced, screening for C. burnetii infection should 
be performed during each pregnancy since the infec-
tion can be contracted at any moment and reactivation 
during pregnancy of a previous infection may occur 
[3,11]. Therefore case finding is a continuing process.
The test and the treatment
Is there a suitable test?
There are several accurate methods to diagnose 
C.  burnetii infection, including culture, PCR and serol-
ogy, of which serology is most suitable for screening 
[17]. However, the performance of these tests dur-
ing pregnancy is unknown. In the general population, 
indirect immunofluorescence assay (IFA) is the refer-
ence method [17,18]. Since one of the characteristics 
of C.  burnetii is antigenetic phase variation, antibod-
ies against two phases of antigens can be detected. 
All types of antibodies have their own timeframe of 
appearance, therefore distinguishing previous, acute 
and chronic infections is possible [12,18]. As already 
mentioned, test characteristics during pregnancy are 
unknown. From other infectious diseases we know 
that false-positive serological results occur quite often 
during pregnancy [19]. Furthermore, with respect to 
sensitivity and specificity, there is an ongoing debate 
about which cut-off values to use, especially because 
there are many different commercial and in-house 
methods. In all, more research needs to be performed 
with respect to serological screening for C.  burnetii 
during pregnancy before routine screening can be 
implemented.
Is the test acceptable to the population?
Acceptance of the test can be expected since only one 
blood sample is necessary, which can be obtained by 
venepuncture combined with the screening for other 
infectious diseases around 12 weeks of pregnancy. An 
advantage of testing in the first trimester is the pos-
sibility of early counselling and treatment during the 
most vulnerable phase of pregnancy [3]. However, with 
early screening, infections later in pregnancy would be 
missed. Timing of the screening needs to be further 
investigated, also taking into account a seasonal varia-
tion in C. burnetii spreading [9].
Is there an accepted treatment for 
patients with recognised disease?
First choice treatment for Q fever among the general 
population is a 14-day antibiotic treatment with doxy-
cycline or fluoroquinolone [12]. However, both agents 
are contraindicated during pregnancy. Long-term treat-
ment with cotrimoxazole has been suggested to be the 
treatment of choice during pregnancy [3]. However, 
use of cotrimoxazole during pregnancy has not been 
fully investigated yet. Pharmacological activity of this 
drug could cause folic acid depletion in the foetus [20]. 
Furthermore, neonatal hyperbilirubinemia has been 
described when used prior to delivery. However, these 
risks turned out to be small in large groups of pregnant 
women with HIV who received prophylactic cotrimox-
azole therapy during pregnancy [21]. In all, more evi-
dence for the best treatment option during pregnancy 
is needed.
Are there facilities for diagnosis 
and treatment available?
Since screening for other infectious diseases dur-
ing pregnancy is already routinely performed, adding 
C. burnetii screening will be relatively straightforward. 
In the Netherlands, as in other Western countries, sev-
eral laboratories have facilities to perform C.  burnetii 
serology. Quality assessments should be performed 
on a regular basis. Treatment and follow-up of posi-
tively screened women should be performed by obste-
tricians, infectious disease specialists and medical 
microbiologist, who should receive additional training 
on diagnostics and treatment of C.  burnetii infection 
during pregnancy.
The costs
Are the costs of case finding economically balanced in 
relation to possible expenditure on medical care as a 
whole?
Figure
Human Q fever incidence per 100,000 inhabitants per 
municipality in the Netherlands, 1 January–12 August 
2009
Incidences are based on symptomatic (fever, pneumonia and/or 
hepatitis), laboratory-confirmed Q fever cases. 
Source: National Institute for Public Health and the Environment 
(RIVM).








Dairy goat and 
dairy sheep 
mandatory Q fever 
vaccination area
4 www.eurosurveillance.org
Outcomes of cost-effectiveness models are not avail-
able yet and input data are required. Screening with IFA 
and antibiotic treatment are relatively cheap, though 
referral for treatment and hospital birth may induce 
high costs since around 25% of the deliveries in the 
Netherlands normally take place at home [22].
The adapted Wilson and Jungner criteria, addressed in 
this study are summarised in the table.
Conclusion
According to the adapted Wilson and Jungner criteria 
(Table), the currently available evidence is insufficient 
to promote routine screening for C.  burnetii infection 
during pregnancy in high-risk Q fever areas. Because 
of potential bias in the studies reported so far, there 
is too much uncertainty about the consequences of 
untreated C. burnetii infection during pregnancy. There 
is also no consensus about the screening method and 
treatment. Furthermore, Q fever incidence rates highly 
affect the effectiveness of screening. Therefore the 
candidate populations for screening are not static and 
should be identified based on epidemiological criteria. 
Finally, besides screening, there are other methods to 
prevent C.  burnetii related complications, for example 
human vaccination [23]. Overall, more evidence about 
the effectiveness of a C.  burnetii screening program, 
in addition to other Q fever prevention and control 
measures taken by the European countries, is needed 
before this infection will become a candidate for rou-
tine screening during pregnancy. 
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